Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Lithium Universe LtdSpodumene Offtake Update
Cardiex Receives TGA Approval for CONNEQT Pulse Device
Ore Reserve Quadruples for Rhyolite Ridge Project; Reaffirms...
Blue Lagoon’s Dome Mountain Joins BC’s Select List...
Harmony Gold to Acquire MAC Copper in US$1.03...
Editor’s Picks: Gold Faces Bumpy Week on Trade...
Charbone Hydrogene annonce les resultats financiers T1 2025
Charbone Hydrogen Announces Q1 2025 Financial Results
Quimbaya Gold Inc. Announces Participation in THE Mining...
Juggernaut Files for Final Approval of Oversubscribed Financing
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Business

DOJ sues Walgreens, alleging it ‘knowingly’ filled millions of invalid prescriptions

by admin January 20, 2025
January 20, 2025
DOJ sues Walgreens, alleging it ‘knowingly’ filled millions of invalid prescriptions

The Department of Justice said Friday that it sued pharmacy giant Walgreens over allegedly dispensing millions of unlawful prescriptions.

The DOJ said that Walgreens from August 2012 until the present “knowingly” filled those prescriptions, which “lacked a legitimate medical purpose, were not valid, and/or were not issued in the usual course of professional practice.” 

“This lawsuit seeks to hold Walgreens accountable for the many years that it failed to meet its obligations when dispensing dangerous opioids and other drugs,” said Principal Deputy Assistant Attorney General Brian Boynton, head of the DOJ’s Civil Division.

Boynton said that Walgreens pharmacists filled millions of prescriptions with “clear red flags that indicated the prescriptions were highly likely to be unlawful.”

The company “systematically pressured its pharmacists to fill prescriptions, including controlled substance prescriptions, without taking the time needed to confirm their validity,” Boynton said. “These practices allowed millions of opioid pills and other controlled substances to flow illegally out of Walgreens stores.”

Some Walgreens patients died of overdose deaths shortly after getting invalid prescriptions filled at Walgreens, the DOJ alleges.

The 300-page lawsuit was filed Thursday in U.S. District Court in Chicago.

Walgreens in a statement said, “We are asking the court to clarify the responsibilities of pharmacies and pharmacists and to protect against the government’s attempt to enforce arbitrary ‘rules’ that do not appear in any law or regulation and never went through any official rulemaking process.”

“We will not stand by and allow the government to put our pharmacists in a no-win situation, trying to comply with ‘rules’ that simply do not exist,” Walgreens said.

“Walgreens stands behind our pharmacists, dedicated healthcare professionals who live in the communities they serve, filling legitimate prescriptions for FDA-approved medications written by DEA-licensed prescribers in accordance with all applicable laws and regulations.”

The suit alleges that although Walgreens issued written policies that reflected its understanding of legal obligations, the company took other actions which it knew prevented its pharmacists from complying with them.

“Walgreens prioritized profits over safety and compliance by implementing policies and practices that required pharmacists to fill prescriptions quickly and left pharmacists without enough time or resources to exercise their corresponding responsibility,” the suit said.

“One such metric was ‘Verify By Promise Time’ (VBPT), which expected a pharmacist to fill a prescription within 15 minutes for a ‘waiter’ (a customer waiting in the pharmacy store for the prescription),” the suit alleges.

“Walgreens also tracked pharmacists that dispensed a low rate of controlled substances through its ‘Non-dispensing Pharmacist Report,’” the suit said.

“Walgreens created this metric in part because it believed pharmacists who refused to fill controlled-substance prescriptions compromised Walgreens’s customer service.”

This post appeared first on NBC NEWS

previous post
Tech 5: Trump to Prioritize Crypto, Biden Blocks AI Chip Exports
next post
S&P 500 climbed 0.3%, and Nasdaq-100 futures jumped 0.7%

You may also like

JPMorgan Chase CEO Jamie Dimon says DOGE ‘needs...

February 26, 2025

Flagging sales and Elon Musk’s political activities are...

March 18, 2025

Eli Manning says ‘only one team’ he’d take...

January 8, 2025

First the token, now the swipe: NYC’s subway...

March 20, 2025

The plane that crashed in South Korea is...

January 3, 2025

Tariff threat looms over the year’s biggest electronics...

January 10, 2025

United CEO expresses ‘renewed confidence’ in Boeing after...

August 16, 2024

Nvidia results spark global chip rally

May 30, 2025

Plummeting stock, boycotts and flagging sales: What’s fueling turmoil for Tesla?

March 18, 2025

Bucking trend, McDonald’s vows no egg surcharges as...

February 27, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Lithium Universe LtdSpodumene Offtake Update

      June 2, 2025
    • Cardiex Receives TGA Approval for CONNEQT Pulse Device

      June 2, 2025
    • Ore Reserve Quadruples for Rhyolite Ridge Project; Reaffirms Robust Project Economics

      June 2, 2025
    • Blue Lagoon’s Dome Mountain Joins BC’s Select List of Permitted Projects

      June 2, 2025
    • Harmony Gold to Acquire MAC Copper in US$1.03 Billion Deal

      June 2, 2025
    Promotion Image

    banner ads

    Categories

    • Business (692)
    • Economy (829)
    • Investing (2,104)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved